Overview

Impact of Immunosuppressive Regimens on Polyomavirus-related Transplant Nephropathy

Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to characterize and evaluate risk factors of polyomavirus nephropathy (PVN) including the impact of three immunosuppressive regimens.
Phase:
Phase 4
Details
Lead Sponsor:
University of Giessen
Collaborators:
Astellas Pharma Inc
Heidelberg University
Hoffmann-La Roche
Novartis
Treatments:
Cyclosporine
Cyclosporins
Everolimus
Immunosuppressive Agents
Mycophenolic Acid
Tacrolimus